Well Referenced

Tag: dopamine agonists

Erectile Dysfunction: Treatments, Advances and New Therapeutic Strategies

This 2023 review outlines current and emerging treatments for erectile dysfunction (ED), affecting approximately 40% of men aged 40–70. First-line therapies include oral phosphodiesterase type 5 inhibitors (PDE5i) such as sildenafil and tadalafil, and intracavernosal injections of agents like prostaglandin E1. Experimental pharmacotherapies under investigation include dopamine D₄ receptor agonists,

Read More »
June 26, 2025 No Comments

Hyperprolactinemia and sexual function in men: a short review

This 2003 review examines the impact of hyperprolactinemia (HPRL) on male sexual function. HPRL is associated with decreased libido, erectile dysfunction, and ejaculatory disorders. While traditionally attributed to reduced testosterone levels, evidence suggests that prolactin may also exert direct effects on central neurotransmitter systems, influencing sexual function independently of testosterone.

Read More »
June 26, 2025 No Comments

The future is today: emerging drugs for the treatment of erectile dysfunction

This review explores emerging drug therapies for erectile dysfunction (ED), discussing both central regulators (clavulanic acid, dopamine and melanocortin receptor agonists) and peripheral regulators (novel PDE5 inhibitors, soluble and particulate guanylyl cyclase activators, rho-kinase inhibitors, and maxi-K channel openers). These emerging treatments offer the potential for individualized approaches tailored to

Read More »
June 26, 2025 No Comments